Mayo Clinic challenges some recommendations in updated cholesterol treatment guideline

August 14, 2014

A Mayo Clinic task force challenges some recommendations in the updated guideline for cholesterol treatment unveiled by the American College of Cardiology (ACC) and American Heart Association (AHA) in 2013. The task force concludes, based on current evidence, that not all patients encouraged to take cholesterol-lowering medications, such as statins, may benefit from them and that the guideline missed some important conditions that might benefit from medication.

Furthermore, the task force believes an emphasis needs to be placed on an individualized treatment approach with each patient and exercising shared decision-making.

Recommendations of the task force, made up of Mayo Clinic experts in cardiology, endocrinology and preventive medicine, with no conflicts of interest or links to the drug industry, will be published Aug. 14 in Mayo Clinic Proceedings. An editorial will accompany the paper. Mayo Clinic physicians are adopting the task force's guideline.

"The ACC/AHA cholesterol guideline was last updated in 2001, so it needed to be updated. We agree with many points of the guideline, but there are some key areas where we do not completely agree or we wanted to expand and provide more guidance," says Francisco Lopez-Jimenez, M.D., task force chairman and director of preventive cardiology at Mayo Clinic in Rochester, Minnesota.

Mayo's cholesterol treatment recommendations challenge some core ACC/AHA recommendations, and go further in-depth in some areas. For example:

* The ACC/AHA cholesterol treatment guideline recommends prescribing the strongest statins at high doses to most men older than 65, even those with no history of heart disease, or any major risk factor for heart attacks, and with normal cholesterol levels. Men this age will be classified as high risk only on the basis of age. The Mayo task force found no evidence from clinical trials to recommend treating people only on the basis of age in the absence of risk factors, high cholesterol or inflammation.

* The ACC/AHA cholesterol treatment guideline recommends cholesterol-lowering medication as a primary preventive measure against , and encourages health care providers to simultaneously emphasize the importance of healthy lifestyle habits. The Mayo task force encourages lifestyle changes—such as exercise and dietary changes—first, followed by re-evaluating risk in three to six months before prescribing statins, especially in motivated patients and with borderline high risk.

* The ACC/AHA cholesterol treatment guideline recommends statins for all people with diabetes mellitus who are 40 years or older. The Mayo task force debunks the concept that all diabetics have the same risk as people with history of heart attacks. The Mayo task force does not recommend in favor of or against the use of statins in patients with diabetes in whom the risk for heart attacks or stroke is low based on the calculator proposed by the ACC/AHA.

In addition, Mayo's task force recommends statins to patients with some conditions that the ACC/AHA guideline did not specifically address, such as patients who have rheumatoid arthritis, recipients of a kidney or heart transplant or those infected with the AIDS virus. These patients are known to have an increased risk of heart attack, Dr. Lopez-Jimenez says.

Second Mayo Clinic task force examined cardiovascular risk assessment guideline

A second Mayo Clinic task force provided a perspective on the new ACC/AHA guideline for assessing cardiovascular risk in patients who do not have heart disease, also released in 2013. The panel recognizes the value of several new features in the guideline, such as specific risk equations for African-Americans, equations to calculate both 10-year and 30-year lifetime risk, inclusion of stroke as an adverse cardiovascular event, and emphasis on shared decision-making.

These recommendations also are published in a second paper Aug. 14 in Mayo Clinic Proceedings.

But there are areas where Mayo's risk assessment task force recommended adaptation of the ACC/AHA's recommendations. For example, the ACC/AHA guideline suggests using family history only when a "risk-based treatment decision is uncertain," says Iftikhar Kullo, M.D., Mayo Clinic cardiologist and chair of the risk assessment task force.

"We recommend that family history should be obtained at the time of estimating cardiovascular risk using the new equations," Dr. Kullo says. "Many studies have shown family history to be an independent predictor of cardiovascular risk. Obtaining family history may also help to identify additional individuals in a family who may be at risk."

Mayo's highlights caveats in the use of ankle-brachial index and C-reactive protein for cardiovascular risk assessment—two tests recommended by the ACC/AHA guideline—and recommends that the following additional tests could be considered to refine estimates of cardiovascular risk:

* An ultrasound test of the carotid (neck) arteries to measure thickness of the lining of the arteries, as well look for presence of plaque.

* A noninvasive test (aortic pulse wave velocity) to measure stiffness in the arteries.

* A blood test to measure lipoprotein(a), a type of LDL (or "bad") cholesterol. Lp (a) level is determined by genes, and high levels are associated with increased .

Both Mayo Clinic task forces also emphasized the importance of individualized care and using shared decision-making tools with patients to decide on treatment and determining heart disease risk. "We encourage an individualized approach, particularly when the evidence is inconclusive to a patient's particular situation," Dr. Lopez-Jimenez says. "In addition, we want to find a treatment—whether it's lifestyle changes or perhaps statins—the patient will follow through with because that is what will help make a difference in cardiovascular prevention."

Explore further: US, European cholesterol guidelines differ in statin use recommendations

Related Stories

US, European cholesterol guidelines differ in statin use recommendations

March 29, 2014
Application of U.S. and European cholesterol guidelines to a European population found that proportions of individuals eligible for statins differed substantially, with one U.S. guideline recommending statins for nearly all ...

Should men at risk for cardiovascular disease receive earlier cholesterol treatment?

July 22, 2014
New guidelines on cholesterol treatment and cardiovascular risk assessment state that men have at least double the risk of dying from atherosclerotic cardiovascular disease or of having a heart attack or stroke as do women ...

Taking statins to lower cholesterol? New guidelines provide opportunity to discuss options with your doctor

February 4, 2014
Clinicians and patients should use shared decision-making to select individualized treatments based on the new guidelines to prevent cardiovascular disease, according to a commentary by three Mayo Clinic physicians published ...

Questions raised in US over new anti-cholesterol guidelines

November 20, 2013
New recommendations to expand the use of cholesterol-lowering medication to millions of adults to reduce heart attacks and strokes overestimated risks faced by that population, according to a new study.

ACC/AHA publish new guideline for management of blood cholesterol

November 12, 2013
The American College of Cardiology and the American Heart Association today released a new clinical practice guideline for the treatment of blood cholesterol in people at high risk for cardiovascular diseases caused by atherosclerosis, ...

Are the new ACC/AHA guidelines for lipids appropriate for people with diabetes?

June 14, 2014
New guidelines for the treatment of high cholesterol are not appropriate for people with type 2 diabetes – or are they? Two researchers will debate the topic at a symposium to be held on Tuesday, June 17, at the American ...

Recommended for you

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

'Fat but fit' are at increased risk of heart disease

August 14, 2017
Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

Study hints at experimental therapy for heart fibrosis

August 14, 2017
Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury—describing an experimental molecular treatment ...

Scientists identify mutations in venous valve disease

August 14, 2017
A team of scientists has discovered that mutations in the genes FOXC2 and GJC2 are associated with defects in venous valves, flaps within veins that help maintain proper blood flow.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.